Table 2.

Model inputs of costs and health utility

	Costs ($)	Utility	References
Drug cost per cycle
Vedolizumab induction phase	1539.4b	–	[30]
Vedolizumab maintenance phase	769.7	–	[30]
Conventional therapya	362.5	–	Expert survey
Administration cost per cyclea	50.7	–	Expert survey
Health state costs per cyclea		Health state utility
Remission	386.8	0.83	[23]
Mild	440.9	0.69	[23]
Moderate-to-severe	1949.9	0.42	[23]
Surgery	10,601.8	0.42	[23, 24]
Costs of AEs per eventa		AE utility decrement
Serious infection	1504.2	− 0.47	[25]
Tuberculosis	815.3	− 0.50	[26]
Malignancy (including lymphoma)	1507.4	− 0.18	[27]
Acute hypersensitivity reactions	234.0	− 0.10	[28]
Skin site reactions	46.8	− 0.03	[29]

AE adverse event

^aThe price information is based on the survey of 18 clinical physicians from 18 tertiary hospitals in China. ^bThe cost was for weeks 0 and 2. A third injection was given if had response at week 6